Anti-tumor necrosis factor-alpha treatment in pediatric patients with pars planitis: a single-center experience from Turkey

Özer M. D., Batur M.

INTERNATIONAL OPHTHALMOLOGY, vol.43, no.1, pp.155-166, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 43 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.1007/s10792-022-02398-z
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE
  • Page Numbers: pp.155-166
  • Keywords: Pars planitis, Anti-TNF-alpha, Macular edema, Intraocular inflammation, Intermediate uveitis, Biologic agent, NONINFECTIOUS UVEITIS, ADALIMUMAB, CHILDREN, STANDARDIZATION
  • Van Yüzüncü Yıl University Affiliated: Yes


Aim To evaluate the effectiveness and safety of anti-tumor necrosis factor-alpha (anti-TNF-alpha) treatment (Adalimumab [ADA]) combined with immunomodulatory agents (IMAs) in the treatment of pars planitis (PP). Methods The patients with PP who were treated with anti-TNF-alpha agents for at least six months were qualified for the chart review. The outcome parameters were the steroid-free remission state, the best-corrected visual acuity (BCVA) and the central macular thickness (CMT) of the patients at the last visit. Results After a mean total follow-up time of 15.5 +/- 5.8 months (8-24 months), all the cases were in steroid-free remission at the last visit. The mean BCVA increased, and the mean CMT decreased significantly at the last visit (p < 0.001, p < 0.001, respectively). Conclusion ADA combined with IMAs offers effective and safe treatment modalities in the control of chronic intraocular inflammation in PP cases.